Earnings Preview For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) is set to release its quarterly earnings report on October 30, 2024. Analysts expect an EPS of $-0.19. The company previously beat EPS estimates, leading to a slight share price increase. Analysts rate ITCI as 'Outperform' with a price target suggesting a 32.88% upside. Despite strong revenue growth, ITCI lags in profitability metrics compared to peers.
October 29, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies is expected to report an EPS of $-0.19. Analysts rate the stock as 'Outperform' with a potential 32.88% upside. The company has shown strong revenue growth but lags in profitability metrics compared to peers.
The upcoming earnings report and analyst ratings are significant for ITCI's stock price. The 'Outperform' rating and potential upside suggest positive sentiment. However, the company's lower profitability metrics compared to peers may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100